Please login to the form below

Not currently logged in
Email:
Password:

fitusiran

This page shows the latest fitusiran news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk hits pause on rival to Hemlibra for haemophilia

Novo Nordisk hits pause on rival to Hemlibra for haemophilia

Meanwhile, another non-clotting factor drug for haemophilia  – Alnylam and Sanofi’s RNA interference candidate fitusiran – is also in late-stage development for haemophilia A and B.

Latest news

  • Sanofi narrows focus, shedding diabetes and cardiovascular research Sanofi narrows focus, shedding diabetes and cardiovascular research

    This includes a host of investigational therapies for rare disease and cancers, such as Fitusiran (an RNAi therapeutic for haemophilia A and B), BIVV001 (a factor VIII therapy for haemophilia A)

  • Roche’s Hemlibra scores broader NHS funding Roche’s Hemlibra scores broader NHS funding

    Competition is heating up in haemophilia, however. Alnylam's late-stage candidate fitusiran is tipped as a major competitor to Hemlibra, while the first gene therapies are also on the horizon.

  • ACPs to lead gene therapies in haemophilia market growth ACPs to lead gene therapies in haemophilia market growth

    New therapies to hit existing players. Roche’s Hemlibra and Alnylam’s late-stage candidate fitusiran are likely to seize a bigger share of an expanded haemophilia market than gene therapies, ... The two drugs have distinct mechanisms –  Hemlibra

  • Sanofi exits R&D pact with Alnylam on rare disease Sanofi exits R&D pact with Alnylam on rare disease

    The R&D deal was tweaked in January last year, with Sanofi licensing an RNAi drug called fitusiran for haemophilia A and B as well as other rare bleeding disorders, but ... Prospects for haemophilia candidate fitusiran looked a little shaky in 2017 when

  • FDA lifts clinical hold on Sanofi’s haemophilia drug FDA lifts clinical hold on Sanofi’s haemophilia drug

    Fitusiran holds the potential to help improve the lives of people living with haemophilia,” said Akin Akinc, who is leading the development of the drug at Alnylam. ... With the additional risk mitigation measures in place, we look forward to the

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....